Top Markets
Coin of the day
Gongwin Biopharm Holdings Co., Ltd. Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd.

6617
Rank in Stocks #13748
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical... Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.
Share Price
$3.83
Market Cap
$464.45M
Change (1 day)
-1.63%
Change (1 year)
17.17%
Country
TW
Trade Gongwin Biopharm Holdings Co., Ltd. (6617)

Category

Earnings for Gongwin Biopharm Holdings Co., Ltd. (6617)
Earnings in 2026 TTM: 0
According to Gongwin Biopharm Holdings Co., Ltd. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Gongwin Biopharm Holdings Co., Ltd. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$6.46B -
US
- -
US
$2.17B -
US
- -
US
$708.86M -
AU